http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Complex Multiplier suited for EPGA structure
Keiichi Satoh,Jubee Tada,Kenta Yamaguchi,Yasutaka Tamura 대한전자공학회 2008 ITC-CSCC :International Technical Conference on Ci Vol.2008 No.7
In this paper, we propose complex multiplier suited for FPGA structure to achieve higher performance and lower cost. The complex multiplier is based on LUT (Look-Up-Table) and carry-chain from FPGA structure, we utilize Booth algorithm for partial product generation and Wallace tree utilizing effectively LUTs and carry-chains in the FPGA structure for the partial products compression to design it. We design Wallace trees of various types utilizing LUTs and carry-chains, the complex multipliers implemented the trees are synthesized by synthesis tool. Consequently, the proposed complex multipliers are superior to one synthesized by operator(’*’,’+’, and ’-’) from VHDL description for both the path delay and the scale.
Keiichi Fujiwara,Hiroyuki Fujiwara,Hiroyuki Yoshida,Toyomi Satoh,Kan Yonemori,Shoji Nagao,Takashi Matsumoto,Hiroaki Kobayashi,Hughes Bourgeois,Philipp Harter,Anna Maria Mosconi,Isabel Palacio Vazquez 대한부인종양학회 2021 Journal of Gynecologic Oncology Vol.32 No.5
Objective: The addition of maintenance olaparib to bevacizumab demonstrated a significant progression-free survival (PFS) benefit in patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1/ENGOT-ov25 trial (NCT02477644). We evaluated maintenance olaparib plus bevacizumab in the Japan subset of PAOLA-1. Methods: PAOLA-1 was a randomized, double-blind, phase III trial. Patients received maintenance olaparib tablets 300 mg twice daily or placebo twice daily for up to 24 months, plus bevacizumab 15 mg/kg every 3 weeks for up to 15 months in total. This prespecified subgroup analysis evaluated investigator-assessed PFS (primary endpoint). Results: Of 24 randomized Japanese patients, 15 were assigned to olaparib and 9 to placebo. After a median follow-up for PFS of 27.7 months for olaparib plus bevacizumab and 24.0 months for placebo plus bevacizumab, median PFS was 27.4 versus 19.4 months, respectively (hazard ratio [HR]=0.34; 95% confidence interval [CI]=0.11–1.00). In patients with tumors positive for homologous recombination deficiency, the HR for PFS was 0.57 (95% CI=0.16–2.09). Adverse events in the Japan subset were generally consistent with those of the PAOLA-1 overall population and with the established safety and tolerability profiles of olaparib and bevacizumab. Conclusion: Results in the Japan subset of PAOLA-1 support the overall conclusion of the PAOLA-1 trial demonstrating that the addition of maintenance olaparib to bevacizumab provides a PFS benefit in patients with newly diagnosed, advanced ovarian cancer. Trial Registration: ClinicalTrials.gov Identifier: NCT02477644